DDAH II Antibodies

Santa Cruz Biotechnology features a diverse variety of DDAH II monoclonal antibodies for research focused on understanding DDAH II's role in various biological processes. DDAH II Antibodies for DDAH II are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). DDAH II, or Dimethylarginine Dimethylaminohydrolase II, plays a crucial role in regulating nitric oxide synthesis by metabolizing asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase. This regulation is vital for maintaining vascular health and has implications in cardiovascular diseases, inflammation, and other pathological conditions. Understanding DDAH II function can provide insights into therapeutic targets for various diseases linked to nitric oxide dysregulation. Research with DDAH II has revealed its significance in multiple cellular pathways and signaling mechanisms. Investigating DDAH II expression patterns helps researchers better understand its involvement in disease progression and potential therapeutic interventions. Current studies continue to uncover new roles for DDAH II in biological processes. Santa Cruz Biotechnology monoclonal antibodies for DDAH II enable researchers worldwide to advance scientific understanding of vascular health and disease mechanisms.